Recipharm makes senior appointments as transition to low global warming potential propellants in pressurised Metered Dose Inhalers gains pace

August 23, 2023

Global contract development and manufacturing organisation (CDMO), Recipharm has today announced the appointment of Richard Turner as Head of Business Development, and Jeremy  Tidmarsh as Site Director, Holmes Chapel, to its Advanced Delivery Systems business unit, as it continues to accelerate its ambition to supply low global warming potential (GWP) pressurised  Metered Dose Inhalers (pMDIs) in response to customer demand.  

Richard joins Recipharm from H&T Presspart, where he was Global Sales Director. Having spent 22  years developing H&T Presspart’s pMDI components business, Richard is ideally placed to lead  Recipharm’s business development team to partner with customers worldwide. Richard and his team will focus on supporting customers with pMDI product development, fully finished clinical and commercial scale pMDI supply, and device and component development and supply, including the market-leading Bespak® range of pMDI valves, actuators, and dose counters. 

Jeremy joins Recipharm from Wockhardt UK, where he was Site Director of technical operations.  Having previously worked for Ipsen Biopharm and Reckitt Benckiser Health, Jeremy brings a wealth of experience in pharmaceutical manufacturing and packing, supply chain, and leadership of global transformation and efficiency programmes. Jeremy and his team will focus on operations to support Recipharm’s growth at the site which supplies pMDIs worldwide, and will further develop its capability to supply low-GWP inhalers. 

These appointments come as Recipharm announced its collaboration with Honeywell to speed up the development of inhalers with a near-zero GWP propellant, Honeywell Solstice® Air (HFO 1234ze(E) cGMP). This announcement follows recent news on the expansion of its pMDI product development and manufacturing capabilities to accommodate increased demand from pharmaceutical companies. 

Commenting on these appointments, Chris Hirst, President of Recipharm’s Advanced Delivery  Systems business unit said: “I am delighted that both Richard and Jeremy have chosen to join  Recipharm at this exciting time as we build our capabilities and capacity to serve our customers in their transition to low-GWP propellant pMDIs. Combined with our collaboration with Honeywell, and  our expertise in valves and actuators under our Bespak® brand, we aim to be the partner of choice  for companies developing their pMDI portfolios to embrace more sustainable respiratory care.” 

Recipharm Advanced Delivery Systems is now Bespak, a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery devices and drug-device combination products.

For further information and interview opportunities with Bespak, please contact:

Sarah Guinane at Notch Communications

[email protected]

About Bespak

Bespak is a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery devices and drug-device combination products. Bespak develops and manufactures finished pharmaceutical products, as well as being a leading global supplier of drug delivery devices and componentry to the pharmaceutical industry. With a long history in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), Bespak supplies a major proportion of the world’s pMDI dosing valves and actuators, and also specialises in the industrialisation and high-volume manufacture of complex dry powder inhaler (DPI) devices.

Headquartered in Holmes Chapel, UK, the company’s service offering spans early-stage feasibility, analytical services and product development, from pilot-scale, through to clinical supply and commercial-scale drug product fill-finish, device and component manufacturing.

More information:

You may also like